Clinical trial
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or…
NCT00095966 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00095966 |
|---|---|
| Title | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate, gemcitabine hydrochloride |
| Enrollment | 35 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2005 |
| First posted | Nov 9, 2004 |
| Last update posted | Jul 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: